Pfizer Limited has reported its audited financial results for the fiscal year ended March 31, 2026. The company achieved a total income of ₹2,707.60 crore, with a net profit of ₹722.43 crore. Demonstrating strong commitment to shareholder returns, the Board has recommended a final dividend of ₹75 per equity share, representing a 750% payout. The company continues to maintain a stable market position in the pharmaceuticals sector.
Financial Performance Overview
For the financial year 2026, Pfizer Limited recorded a solid revenue performance, with revenue from operations reaching ₹2,519.65 crore. The company reported a net profit of ₹722.43 crore. These audited figures reflect the company’s operational efficiency and steady growth throughout the year, sustaining its position within the competitive pharmaceutical landscape.
Dividend Recommendation
The Board of Directors has recommended a significant final dividend of ₹75 per equity share (on a face value of ₹10 each). This translates to a 750% dividend payout for the financial year. Subject to shareholder approval at the upcoming Annual General Meeting, the dividend is scheduled to be paid on or after August 4, 2026, to shareholders registered as of July 17, 2026.
Annual General Meeting and Governance
The 75th Annual General Meeting of the company is scheduled to take place on Tuesday, July 28, 2026. In line with modern governance practices, the meeting will be conducted via Video-Conferencing or Other Audio-Visual Means. Furthermore, the company has appointed M/s. Kishore Bhatia & Associates as the new Cost Auditors for the financial year ending March 31, 2027, ensuring continued focus on financial oversight and compliance.
Operational Highlights
The company noted specific impacts on its financial statements due to exceptional items, including costs associated with personnel separation and adjustments for new labor codes implemented by the Government of India. Despite these adjustments, the company maintains a robust financial profile and continues to focus exclusively on its core Pharmaceuticals business segment.
Source: BSE
